These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 14964752)

  • 41. Successful treatment of hand and foot psoriasis with efalizumab therapy.
    Fretzin S; Crowley J; Jones L; Young M; Sobell J
    J Drugs Dermatol; 2006 Oct; 5(9):838-46. PubMed ID: 17039648
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Population pharmacokinetics of efalizumab (humanized monoclonal anti-CD11a antibody) following long-term subcutaneous weekly dosing in psoriasis subjects.
    Sun YN; Lu JF; Joshi A; Compton P; Kwon P; Bruno RA
    J Clin Pharmacol; 2005 Apr; 45(4):468-76. PubMed ID: 15778428
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Palmoplantar subcorneal pustular dermatosis following adalimumab therapy for rheumatoid arthritis.
    Sauder MB; Glassman SJ
    Int J Dermatol; 2013 May; 52(5):624-8. PubMed ID: 23489057
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ramipril-induced generalized pustular psoriasis: case report and literature review.
    Thakor P; Padmanabhan M; Johnson A; Pararajasingam T; Thakor S; Jorgensen W
    Am J Ther; 2010; 17(1):92-5. PubMed ID: 19531936
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Approaches to discontinuing efalizumab: an open-label study of therapies for managing inflammatory recurrence.
    Papp KA; Toth D; Rosoph L
    BMC Dermatol; 2006 Oct; 6():9. PubMed ID: 17067371
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A diagnostic challenge: acute generalized exanthematous pustulosis or pustular psoriasis due to terbinafine.
    Duckworth L; Maheshwari MB; Thomson MA
    Clin Exp Dermatol; 2012 Jan; 37(1):24-7. PubMed ID: 21790726
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Rebound of psoriasis after efalizumab discontinuation, despite being on high-dose cyclosporine.
    Maskatia ZK; Koo J
    J Drugs Dermatol; 2007 Sep; 6(9):941-4. PubMed ID: 17941368
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical effectiveness and safety experience with efalizumab in the treatment of patients with moderate-to-severe plaque psoriasis in Taiwan: results of an open-label, single-arm pilot study.
    Tsai TF; Liu MT; Liao YH; Licu D
    J Eur Acad Dermatol Venereol; 2008 Mar; 22(3):345-52. PubMed ID: 18005021
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Delayed generalized inflammatory psoriasis flare during efalizumab treatment.
    Martin B; Sánchez-Carazo JL; Pérez-Ferriols A; Oliver V; Alegre V
    Br J Dermatol; 2009 Jul; 161(1):212-3. PubMed ID: 19438856
    [No Abstract]   [Full Text] [Related]  

  • 50. Ustekinumab treatment of TNF antagonist-induced paradoxical psoriasis flare in a patient with psoriatic arthritis: case report and review.
    Puig L; Morales-Múnera CE; López-Ferrer A; Geli C
    Dermatology; 2012; 225(1):14-7. PubMed ID: 22890275
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Rebound of psoriasis during treatment with efalizumab.
    Golda N; Benham SM; Koo J
    J Drugs Dermatol; 2006 Jan; 5(1):63-5. PubMed ID: 16468294
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impetigo herpetiformis responsive to secukinumab.
    Chhabra G; Chanana C; Verma P; Saxena A
    Dermatol Ther; 2019 Sep; 32(5):e13040. PubMed ID: 31361940
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Relapse, rebound, and psoriasis adverse events: an advisory group report.
    Carey W; Glazer S; Gottlieb AB; Lebwohl M; Leonardi C; Menter A; Papp K; Rundle AC; Toth D
    J Am Acad Dermatol; 2006 Apr; 54(4 Suppl 1):S171-81. PubMed ID: 16488339
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Infantile generalized pustular psoriasis: successful disease control with intermittent etretinate.
    Namba C; Murakami M; Hanakawa Y; Tohyama M; Shirakata Y; Tauchi H; Sayama K
    J Dermatol; 2014 May; 41(5):403-6. PubMed ID: 24801915
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics.
    Papoutsaki M; Chimenti MS; Costanzo A; Talamonti M; Zangrilli A; Giunta A; Bianchi L; Chimenti S
    J Am Acad Dermatol; 2007 Aug; 57(2):269-75. PubMed ID: 17574299
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Anterior chest wall arthritis and osteitis associated with Sneddon-Wilkinson disease.
    Belfiore N; Caporali R; Borroni G; Montecucco C
    Clin Exp Rheumatol; 1997; 15(6):667-9. PubMed ID: 9444425
    [TBL] [Abstract][Full Text] [Related]  

  • 57. New biologics for psoriasis and psoriatic arthritis.
    Rozenblit M; Lebwohl M
    Dermatol Ther; 2009; 22(1):56-60. PubMed ID: 19222517
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Successful treatment with adalimumab in a patient with psoriatic arthritis and generalized pustular psoriasis.
    Kimura U; Kinoshita A; Sekigawa I; Takamori K; Suga Y
    J Dermatol; 2012 Dec; 39(12):1071-2. PubMed ID: 22506677
    [No Abstract]   [Full Text] [Related]  

  • 59. [Extra-cutaneous systemic manifestations in generalized pustular psoriasis].
    Benomar S; Belgnaoui F; Meziane M; Senouci K; Hassam B
    Rev Med Interne; 2010 Jul; 31(7):e16-8. PubMed ID: 20627478
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Generalized pustular psoriasis-like eruptions induced after the first use of adalimumab in the treatment of psoriatic arthritis.
    Kimura U; Kinoshita A; Haruna K; Mizuno Y; Sekigawa I; Takamori K; Suga Y
    J Dermatol; 2012 Mar; 39(3):286-7. PubMed ID: 21957978
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.